Ishita Drugs & Industries Ltd

Ishita Drugs' latest Q2 FY26 results are concerning, showing a 43.15% decline in net sales and a 53.33% drop in net profit compared to the previous quarter, indicating significant operational challenges and cash flow issues.

As of 28-Oct, Ishita Drugs & Industries Ltd's stock price is declining at 72.10, down 1.93%, and has underperformed its sector. The stock is on a downward trend, trading below all key moving averages, with a year-to-date decline of 22.00%, contrasting with the Sensex's gain of 8.30%.

Ishita Drugs has shown mixed historical performance, with net sales slightly decreasing to 15.00 Cr in March 2025, while profits improved, including a profit after tax of 0.87 Cr. However, the company faces cash flow challenges, reporting -3.00 Cr in operating cash flow for the same period.

Ishita Drugs has shown mixed historical performance, with net sales increasing to 15.00 crore in March 2025, alongside improved profitability metrics, but facing challenges with cash flow and rising liabilities. Total assets and liabilities both grew to 16.30 crore, indicating financial strain despite profit growth.

As of 20-Oct, Ishita Drugs & Industries Ltd is seeing a price increase to Rs 76.99, up 5.22%, following a trend reversal after three days of decline. Despite this short-term recovery, the stock has declined 4.99% over the past month and 16.70% year-to-date, indicating longer-term concerns.

As of 17-Oct, Ishita Drugs & Industries Ltd is facing a decline in its stock price, currently at 73.17, down 0.68%. The stock has underperformed its sector and is on a bearish trend, with significant declines over various time frames compared to the Sensex, which has gained.

Ishita Drugs has shown mixed historical performance, with net sales slightly decreasing to 15.00 Cr in March 2025 but profits increasing, including a rise in profit after tax to 0.87 Cr. However, the company faces challenges with negative cash flow from operations and rising liabilities.

As of 01-October, Ishita Drugs & Industries Ltd's stock price is Rs 77.12, down 5.26%, with a significant decline in delivery volume and underperformance compared to its sector. Despite long-term gains, recent trends indicate a troubling short-term outlook with a year-to-date decline of 16.56%.

As of 24-Sep, Ishita Drugs & Industries Ltd is currently priced at Rs 83.00, reflecting a recent rise and strong performance, outperforming its sector and the benchmark Sensex. Despite a negative year-to-date return, the stock has shown resilience with positive financial results, though concerns about long-term fundamentals remain.

As of the latest available date, Ishita Drugs' stock has risen by 5.25% over the past week and 7.90% over the past month, outperforming the Sensex. However, it is down 11.30% year-to-date, despite a 4.51% increase over the past year and a significant 246.68% rise over the last five years.

As of 22-Sep, Ishita Drugs & Industries Ltd is priced at 80.00, down 1.27%. The stock has shown short-term gains but has a year-to-date decline of 13.45%, with a significant drop in delivery volume indicating reduced investor confidence.

As of 19-Sep, Ishita Drugs & Industries Ltd is seeing a price increase to Rs 81.00, up 2.53%, with strong recent performance but declining investor participation. Despite a year-to-date decline, the stock has a robust long-term return of 289.42% over five years.